Clinical Applications Of Circulating Tumor Cells And Circulating Tumor Dna As Liquid Biopsy Pdf
- and pdf
- Saturday, January 16, 2021 6:26:08 AM
- 5 comment
File Name: clinical applications of circulating tumor cells and circulating tumor dna as liquid biopsy .zip
- Liquid Biopsy Applications in the Clinic
- Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
- Perspectives of the Application of Liquid Biopsy in Colorectal Cancer
Circulating tumour cells CTCs refer to cells found in the peripheral blood, which are derived from the primary or secondary tumour. They serve as an alternative to study the biology of the primary tumour especially when tissue biopsy is not available. However, major challenges in CTC analysis are the rarity of these cells and the purity of the isolated population. The advancement in technologies allows detection and enrichment of sufficiently pure CTCs at the single-cell level, facilitating downstream molecular characterisation.
Liquid Biopsy Applications in the Clinic
Colorectal cancer CRC is one of the most common gastrointestinal tumors and the second leading cause of cancer death worldwide. Since traditional biopsies are invasive and do not reflect tumor heterogeneity or monitor the dynamic progression of tumors, there is an urgent need for new noninvasive methods that can supplement and improve the current management strategies of CRC. Blood-based liquid biopsies are a promising noninvasive biomarker that can detect disease early, assist in staging, monitor treatment responses, and predict relapse and metastasis. Over time, an increasing number of experiments have indicated the clinical utility of liquid biopsies in CRC. In this review, we mainly focus on the development of circulating tumor cells and circulating tumor DNA as key components of liquid biopsies in CRC and introduce the potential of exosomal microRNAs as emerging liquid biopsy markers in clinical application for CRC. Colorectal cancer CRC is one of the most common gastrointestinal tumors and the second leading cause of cancer death worldwide [ 1 ].
Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer
Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients. The sources of these late relapses are disseminated tumor cells DTCs or small micrometastases undetectable by current imaging procedures. Indeed, the rate of subsequent distant recurrence is significantly higher in patients with detectable DTCs than in those without [ 1 ]. In this context, the high plasticity of cancer cells plays an important role. Carcinoma cells can undergo an epithelial-to-mesenchymal transition, which is associated with cancer cell stemness leading to an increased invasiveness and resistance to chemotherapy.
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
Metrics details. Hepatocellular carcinoma HCC is a highly malignant disease with a poor prognosis and high mortality due to a low early diagnosis rate, resistance to systemic treatments and progression to late-stage liver disease. Thus, it is imperative to establish a novel diagnostic strategy with high sensitivity and reliability to monitor risk factors to detect HCC at an early stage. As a noninvasive detection method, liquid biopsy is expected to play an important role in the early diagnosis, dynamic monitoring of cancer patients and drug screening.
As one of the most common malignant tumors worldwide, hepatocellular carcinoma HCC is known for its poor prognosis due to diagnosis only in advanced stages. Currently, the advancements in the integration of omics information have begun to transform the clinical management of cancer patients. Molecular profiling for HCC patients is in general obtained from resected tumor materials or biopsies. However, the resected tumor tissue is limited and can only be obtained through surgery, so that dynamic monitoring of patients cannot be performed.
One application of liquid biopsy technology is the diagnosis of disease using biomarkers found in blood, urine, stool, saliva, and other biological samples from patients. More recently, the use of cell-free DNA from plasma is emerging as an important minimally invasive tool for clinical diagnosis.
Perspectives of the Application of Liquid Biopsy in Colorectal Cancer
International Journal of Biological Sciences. Journal of Cancer. Journal of Genomics. Global reach, higher impact. Journal of Genomics - Submit manuscript now
Liquid biopsy of HCC: circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are easily accessible in peripheral blood of patients.
chapter and author info
Skip to search form Skip to main content You are currently offline. Some features of the site may not work correctly. DOI: Pantel Published Medicine Cancer discovery. Analyses of CTCs and ctDNA have paved new diagnostic avenues and are, to date, the cornerstones of liquid biopsy diagnostics.
Betasciencepress Publishing. Published 15 August Download PDF.
Ovarian cancer remains the most lethal disease among gynecological malignancies despite the plethora of research studies during the last decades. The majority of patients are diagnosed in an advanced stage and exhibit resistance to standard chemotherapy. Both have shown a diagnostic, prognostic and predictive value in many types of solid malignancies and recent studies attempted to shed light on their role in ovarian cancer. This review is mainly focused on the clinical value of both CTCs and ctDNA in ovarian cancer and, more specifically, on their potential as diagnostic, prognostic and predictive tumor biomarkers.
Betasciencepress Publishing. Published 15 August